TRUPCR® BCR-ABL1 Transcript Screening Kit is a RT-qPCR test for the detection and differentiation of BCR-ABL fusion transcripts in bone marrow or peripheral blood samples. The kit provides an advantage over other commercial kits by detecting and differentiating 12 known breakpoint cluster regions in separate tubes, making it one of the most unique and comprehensive solution currently available.
Principle and Procedure:
It has one-step protocol in which total RNA is reverse-transcribed, and the generated cDNA is amplified by PCR using a pair of specific primers and a specific internal double-dye probe of BCR-ABL1 and endogenous control gene ABL1 to monitor the quality and quantity of extracted RNA.
Key Features:
- Detection and differentiation of 12 BCR-ABL1 fusion gene transcripts (e13a2, e13a3, e14a2, e14a3, e1a2, e1a3, e19a2, e19a3, e6a2, e6a3, e8a2 & e8a3) in single test.
- One step kit for fast (~ 90 min) screening of BCR ABL1 status of patient.
- Covering rare transcript like e6a2, e6a3, e8a2 & e8a3 making it most comprehensive solution for BCR ABL1 screening at clinical settings.
- All inclusive kit: The Assay includes cDNA preparation components and all the PCR components including PCR Pre-mix / mastermix for optimized results.
- Positive control for all the transcripts included in the kit for reliable results
Ordering Information:
CAT. NO. | PRODUCT | CONTENTS |
---|---|---|
3B1239 | TRUPCR® BCR-ABL1 Transcript Screening Kit | 48 Reactions |
3B1238 | TRUPCR® BCR-ABL1 Transcript Screening Kit | 96 Reactions |
Publications :
- Singh, Neetu, et al. "Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and-resistant BCR-ABL-dependent chronic myeloid leukemia." Oncotarget 9.54 (2018): 30385.
- Chadha, Ritu, et al. "Cytogenetic Risk Stratification of B-Acute Lymphoblastic Leukemia and Its Correlation with Other Prognostic Factors." Indian Journal of Hematology and Blood Transfusion 39.1 (2023): 141-145.
- Dey, Samya, et al. "Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study." Cancer Treatment and Research Communications 33 (2022): 100635.